Fair / 06/03/2019 - 06/06/2019
BIO International Convention
The BIO International Convention, the world's largest biotechnology trade fair, will take place in Philadelphia, USA from June 3 – 6, 2019. The Fraunhofer Group for Life Sciences will present its research in the area of therapeutic development, medical engineering, healthy foods, environmental research, and biobased economy at the »German Pavilion«. A special focus this year will be on »preclinical models«. In-silico, in-vitro, and in-vivo models are available to clarify specific questions on mechanisms of action or safety issues.
The Fraunhofer institutes mentioned below will present their research at the Fraunhofer-Gesellschaft’s booth. The focus in 2019 will be on the following topics:
Focus lung and airway diseases and infectious diseases
- Process development and manufacturing of active biopharmaceutical ingredients and IMPs according to GMP
- Preclinical models
- Early-phase clinical trials
Also discover more about the Fraunhofer Institute for Toxicology and Experimental Medicine’s ITEM, Hannover Medical School’s (MHH), and the Institute for Glycomics (IfG) of Griffith University in Gold Coast, Australia‘s iCAIR® (Fraunhofer International Consortium for Anti-Infective Research) project. This research alliance has the goal to close the gap between the discovery of new substances and the further development of drug candidates by pharmaceutical industry. The focus is on infectious diseases that are caused by antibiotic-resistant pathogens.
The Bioanalytics and Bioprocesses Branch of the Fraunhofer Institute for Cell Therapy and Immunology IZI-BB focusses on the development of platform technologies and biotechnological applications in agriculture, food safety and environmental testing as well as drug development and diagnostics. Fraunhofer IZI-BB has been developing point-of-care diagnostics for more than a decade. Our goal is to provide new technology platforms that deliver fast and accurate results based on our customer needs. Among those developments are e.g. a quantitative 15-sec Immunoassay format with multiple body fluids as specimens, or an in-vitro diagnostic (ivD) platform containing a handy cartridge and suitable for the detection of DNA, RNA and proteins. Furthermore, we have developed a platform for expressing hard to obtain proteins via cell-free synthesis. Products such as membrane proteins, site specific modifications as well as antibodies have been implemented successfully into the platform.
Booth number: 2008 at the German Pavilion